ProStrakan delays IPO

A flurry of press reports in the UK indicates that ProStrakan will delay the sale of shares in its market debut. Morgan Stanley has been working to drum up interest in the flotation despite a terrible market environment that has forced a string of biotechs to scrap plans for going public in recent weeks.

- read this story from Marketwatch for more

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.